StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Stock analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

Shares of LPCN stock opened at $3.01 on Monday. Lipocine has a fifty-two week low of $2.91 and a fifty-two week high of $11.79. The stock’s fifty day moving average price is $3.54 and its two-hundred day moving average price is $4.47. The company has a market cap of $16.10 million, a PE ratio of -3.96 and a beta of 1.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC lifted its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.